• Home
  • Science
    • ImmunoBody®
    • Moditope®
    • Glymab®
    • Publications
  • Pipeline
  • News
  • Investors
    • Share Info
    • Financial Info
    • Documents & Presentations
    • Corporate Governance
  • Contact Us
    • Find a trial
    • Become an Investigator

Scancell announces further positive data from the ongoing SCOPE trial of SCIB1 with double CPIs for Advanced Melanoma

by chantal | Nov 18, 2024 | Latest News, Regulatory News, SCIB1

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

21st Association for Cancer Immunotherapy (CIMT) Annual Meeting, Mainz, May 2024

by chantal | Jun 11, 2024 | Modi-1, SCIB1, Vaccines

21st Association for Cancer Immunotherapy (CIMT) Annual Meeting, Mainz, May 2024 A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced unresectable melanoma Samantha Paston, Heather Shaw, Poulam Patel, Miranda...

Seventh International Cancer Immunotherapy Conference (CICON23), Milan, September 2023

by chantal | Sep 25, 2023 | Antibodies, Avidimab, Glymab, Moditope, Vaccines

Seventh International Cancer Immunotherapy Conference (CICON23), Milan, September 2023 Unlocking the unique potential of AvidiMab® in fighting cancer Bubacarr G Kaira, Foram Dave, Elena Dubinina, Omar Mohammed, Bryony Heath, Poonam Vaghela, Ruhul Choudhury, Tina...
Next Entries »

Recent Posts

  • Active Immunotherapy: Ready For Prime Time
  • Strategic transactions to unlock longer-term value
  • Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing
  • iSCIB1+ pivotal trial plans advancing
  • AACR (American Association for Cancer Research) Annual Meeting, April 2026, San Diego, California

Recent Comments

No comments to show.

Scancell is focused on developing novel immunotherapies for the treatment of cancer and was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham in the UK.

  • Follow
  • Follow

Science
Our Pipeline
News
Contact Us
Find a Trial
Become an Investigator

ACTIVE IMMUNOTHERAPY

ImmunoBody®
Moditope®

ANTIBODIES

GlyMab®
AvidiMab®

Investors
Company Profile
Advisors
Corporate Governance
Documents & Presentations
Share Information
Financial Information

Copyright © 2026 Scancell | Website Designed & Developed by Identity Creative | Privacy & Cookie Policy